SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Grever MR, Chabner BA. Cancer drug discovery and development. In: DeVitaVT, Jr., HellmanS, RosenbergSA, editors. Cancer. Principles and practice of oncology. Philadelphia: J.B. Lippincott, 1997: 38594.
  • 2
    Cohen MA, Minsky BD, Schilsky RL. Cancer of the colon. In: DeVitaVT, Jr., HellmanS, RosenbergSA, editors. Cancer. Principles and practice of oncology. Philadelphia: J.B. Lippincott, 1997: 114497.
  • 3
    Bolin RW, Robinson WA, Sutherland J, Hamman RF. Busulfan versus hydroxyurea in long term therapy of chronic myelogenous leukemia. Cancer 1982;50: 16832.
  • 4
    Engstrom PF, Macintyre JM, Mittelman A, Klaassen DJ. Chemotherapy of advanced colorectal carcinoma: fluorouracil alone vs two drug combinations using fluorouracil, hydroxyurea, semustine, decarbazine, razoxane, and mitomycin. Am J Clin Oncol 1984;7: 3138.
  • 5
    Agrawal KC, Sartorelli AC. The chemistry and biological activity of α-(N)-heterocyclic carboxaldehyde thiosemicarbazones. Prog Med Chem 1995;15: 32156.
  • 6
    Liu M-C, Lin T-S, Sartorelli AC. Chemical and biological properties of cytotoxic α-(N)-heterocyclic carboxaldehyde thiosemicarbazones. Prog Med Chem 1995;32: 135.
  • 7
    Deconti RC, Toffness BR, Agrawal KC, Tomchick R, Mead JAR, Bertino JR, et al. Clinical and pharmacological studies with 5-hydroxy-2-formylpyridine hydrazone. Cancer Res 1972;32: 145562.
  • 8
    Krakoff IH, Etcubanas E, Tan C, Mayer K, Bethune V, Burchenal JH. Clinical trial of 5-hydroxypicolinaldehyde thiosemicarbazone (5-HP; NSC-107392), with special reference to its iron-chelating properties. Cancer Chemother Rep 1974;58: 20712.
  • 9
    Schaper K-J, Seydel JK, Rosenfeld M, Kazda J. Development of inhibitors of mycobacterial ribonucleotide reductase. Lepr Rev 1986;57: 25464.
  • 10
    Easmon J, Heinisch G, Hofmann J, Langer T, Grunicke HH, Fink J, et al. Thiazolyl and benzothiazolyl hydrazones derived from α-(N)-acetylpyridines and diazines: synthesis, antiproliferative activity and CoMFA studies. Eur J Med Chem 1997;32: 397408.
  • 11
    Kulkarni MV, Patil VD. Synthesis, spectral studies and anti-inflammatory activity of some new 2-aryloxybenzimidazoles. Arch Pharm (Weinheim) 1981;314: 4407.
  • 12
    Katz L. 1953. Antituberculous compounds, III. Benzothiazole and benzoxazole derivatives. J Am Chem Soc 1953;75: 7124.
  • 13
    Bednyagina NP, Postovskii IYA. Benzazoles. 2-Hydrazino- and 2-azidobenzimidazoles. Zh Obshch Khim 1960;30: 14317; Chem Abstr 1961;55:1586.
  • 14
    Easmon J, Heinisch G, Holzer W. Pyridazines 47. The configuration of novel thiosemicarbazone derivatives of pyridazinecarbaldehydes and alkyl pyridazinyl ketones. Heterocycles 1989;29: 1399408.
  • 15
    Akiyama SA, Fojo A, Hanover JA, Pastan I, Gottesman MM. Isolation and genetic characterization of human KB cell lines resistant to multiple drugs. Cell Mol Genet 1985;11: 11726.
  • 16
    Yen Y, Grill SP, Dutschman GE, Chang C-N, Zhou BS, Cheng Y-C. Characterization of a hydroxyurea-resistant human KB cell line with supersensitivity to 6-thioguanine. Cancer Res 1994;54: 368691.
  • 17
    Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990;82: 110712.
  • 18
    Mosman T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65: 5563.
  • 19
    Hamburger AW, Salmon SE. Primary bioassay of human tumor stem cells. Science 1977;197: 4613.
  • 20
    Nocentini G, Federici F, Franchetti P, Barzi A. 2,2′-Bipyridyl-6-carbothioamide and its ferrous complex: their in vitro antitumoral activity related to inhibition of ribonucleotide reductase R2 subunit. Cancer Res 1993;53: 1926.
  • 21
    Taylor IW. A rapid single step staining technique for DNA analysis by flow microfluorimetry. J Histochem 1980;28: 10214.
  • 22
    Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi CA. Rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 1991;139: 2719.
  • 23
    Easmon J, Heinisch G, Pürstinger G, Langer T, Ö sterreicher JK, Grunicke HH, et al. Azinyl and diazinyl hydrazones derived from aryl N-heteroaryl ketones: synthesis and antiproliferative activity. J Med Chem 1997;40: 44205.
  • 24
    Scholz CC, Berger DP, Winterhalter BR, Henss H, Fiebig HH. Correlation of drug response in patients and in the clonogenic assay with solid human tumor xenografts. Eur J Cancer 1990;26: 9015.
  • 25
    Linke SP, Clarkin KC, Di Leonardo A, Tsou A, Wahl GM. A reversible, p53-dependent Go/G1 cell cycle arrest induced by ribonucleotide depletion in the absence of detectable DNA damage. Gene Dev 1996;10: 93447.
  • 26
    Weinstein JN, Myers TG, O'Connor PM, Friend SH, Fornace AJ, Jr., Kohn KW, et al. An information-intensive approach to the molecular pharmacology of cancer. Science 1997;275: 3439.